Ageas announces the Ordinary and Extraordinary General Meetings of Shareholders of ageas SA/NV Ageas announces the Ordinary and Extraordinary General Meetings of Shareholders of ageas SA/NV As the quorum required for the Extraordinary General Meeting of Shareholders of Wednesday 22 April 2026 will not be attained, ageas SA/NV is organising the Ordinary and Extraordinary General Meetings of Shareholders (the "Meeting") on Wednesday 20 May 2026 at 10:30am. The Meeting is being held at the Auditorium of AG Insurance, AG Campus, in 1000 Brussels, Rue du Pont Neuf 17. The general conditions ...
Ageas annonce les Assemblées Générales Ordinaire et Extraordinaire des Actionnaires d’ageas SA/NV Ageas annonce les Assemblées Générales Ordinaire et Extraordinaire des Actionnaires d’ageas SA/NV Étant donné que le quorum requis pour l’Assemblée Générale Extraordinaire des Actionnaires du mercredi 22 avril 2026 ne sera pas atteint, ageas SA/NV organisera les Assemblées Générales Ordinaire et Extraordinaire des Actionnaires (« l’Assemblée ») le mercredi 20 mai 2026 à 10h30. L’Assemblée se tiendra à l’Auditorium d’AG Insurance, AG Campus, Rue du Pont Neuf 17 à 1000 Bruxelles. Les modalités...
Ageas kondigt de Gewone en Buitengewone Algemene Vergaderingen van Aandeelhouders van ageas SA/NV aan Ageas kondigt de Gewone en Buitengewone Algemene Vergaderingen van Aandeelhouders van ageas SA/NV aan Aangezien het vereiste quorum voor de Buitengewone Algemene Vergadering van Aandeelhouders van woensdag 22 april 2026 niet zal worden bereikt, organiseert ageas SA/NV op woensdag 20 mei 2026 om 10u30 de Gewone en Buitengewone Algemene Vergaderingen van Aandeelhouders (de “Vergadering”). De Vergadering zal plaatsvinden in het Auditorium van AG Insurance, AG Campus, Nieuwbrug 17, te 1000 Br...
After a strong set of FY25 results, even excluding for the tax one-off in China, this year is likely to bring the integration of its UK acquisitions (ESURE and SAGA), but also the 25% in AG Insurance (Belgian ops) that is bought from BNP PARIBAS (Not Rated, €91.10) in December 2025, and that should close normally in 2Q26. All these changes are likely to carry some execution risk, notably in the UK if the P&C cycle does not turn. While also we try to model as best we can these new earning streams...
Ageas: FY25 results of CTIH. ASR: Management & Supervisory Board changes. MICC: Preview 1Q26. Ontex: 1Q26 preview - markets remain challenging. Randstad: Preliminary preview 1Q26F results due 22 April. Tessenderlo: 2H25 miss, soft 2026F guidance. Unicredit: Injecting capital into its Belgian Bank
Ekopak's FY25 results, while showing tighter cost discipline, were overshadowed by the withdrawal of the EPICO infrastructure fund from the Waterkracht project—creating the risk of significant operational delays or even full project loss. Although a new partnership with an infrastructure fund is intended to finance large WaaS installations through off balance sheet SPVs, the first joint project award is yet to be announced. With Waterkracht removed from our numbers, valuation remains demanding, ...
Sequana announces progress in the commercial uptake of the alfapump. We estimate at least 8 implants across 5 hospitals since launch in 2H25. The soft-launch target was 70 implants by end of 1Q26. However, we view this target as challenging to reach. We therefore await FY25 results for greater visibility on definitive sales figures and launch metrics. We reiterate our BUY and € 2.7 TP.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.